关于在卵巢癌中对多聚ADP-ribose聚合酶抑制剂耐药性的最新情况

Ruihong Dong1,2, Ting Ding1,2, Zhengyu Li1,2

  • 1Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China.

PubMed
概括

聚基基聚合酶 (PARP) 抑制剂对于治疗卵巢癌至关重要,但面临抗药性. 本综述探讨了抗药性机制和组合策略,以提高治疗疗效.